Every drug approved for spinal muscular atrophy until this month worked on the same problem: the missing SMN protein that causes motor neurons to fail. On September 11, the FDA approved the first one that works somewhere else. Isembyld, from Scholar Rock, is a muscle-targeting therapy, and its approval changes what SMA treatment means: the disease is now fought on two fronts, in the nerve and in the muscle.
The FDA's announcement describes Isembyld as the first therapy to target muscle loss in the disease, approved for adults and children aged two and older who are already receiving an SMN-targeted treatment such as nusinersen or risdiplam. It is an add-on, not a replacement, given as an intravenous infusion every four weeks.
The disease's scale gives the approval its context. SMA affects about one in 10,000 births, and roughly 10,000 children and adults live with it in the United States, Reuters reported. Globally, the company estimates about 35,000 patients have received an SMN-targeted therapy, which makes them, in principle, eligible for the drug that now layers on top of it.
What the Trial Showed
The approval rests on SAPPHIRE, a Phase III trial of 188 patients aged 2 to 21 who could not walk and were already on standard neuron-directed therapy. The study's central result is a contrast that tells the field's story in one line: patients who received Isembyld at the approved dose gained an average of 2.2 points on a 76-point motor function scale over a year, while patients on placebo lost function over the same period, despite their continuing treatment.
The magnitude deserves plain language. A 2.2-point improvement on the Hammersmith scale is a real change in daily motor ability, the difference between needing help with a task and doing it alone for some patients, but it is not a reversal of the disease. The more striking statistic is the responder rate: 34.2% of treated patients achieved a clinically meaningful three-point gain, against 13.5% on placebo. The trial's higher dose did not show significant benefit, and the statistical tests were nominal rather than corrected, an honest wrinkle the company's materials do not hide.
The most sobering finding is the placebo arm itself. Patients receiving the best existing therapy continued to decline over the year they were studied. That decline is what the new drug slows or reverses for some, and it is also the proof that standard treatment was never the whole answer.
The trial's dosing detail is worth knowing. The approved dose is 10 milligrams per kilogram, and the study also tested twice that amount, which did not show significant benefit. The approval is thus built on the lower dose's data, and the drug's launch will proceed on the dose the data supports rather than the highest one the trial explored. Nearly all participants, 98%, enrolled in a long-term extension study, which will report on durability.
Two Fronts in One Disease
SMA is caused by a genetic defect that destroys motor neurons, and the modern therapies, nusinersen, risdiplam, and the gene therapy Zolgensma, all act upstream of that defect to preserve the neuron. Isembyld acts downstream, in the muscle. The drug is an antibody that inhibits myostatin, the protein that puts a brake on muscle growth. Removing the brake lets muscle rebuild.
The architecture of the disease explains why both layers are needed. A neuron kept alive by an SMN therapy can still fail to move a muscle that has wasted away, and a muscle given permission to grow still needs a working nerve to command it. The approved label captures that logic precisely: Isembyld is for patients who are already receiving an SMN-targeted treatment. The combination is not a convenience. It is the therapy, and the trial's design, adding the muscle drug on top of the nerve drugs, is the first proof that the two-layer model works in people.
The two-front logic explains why the combination, not the replacement, is the approved use. A patient whose neurons are preserved by an SMN therapy but whose muscles have wasted needs both: the neuron kept alive, and the muscle given permission to grow. The trial's design, adding Isembyld on top of existing treatment, is the first clinical proof that this layering works in patients.
The science also explains the label's main caution. Muscles growing quickly under a released brake can outpace bone, and the trial recorded fractures in 9% of treated patients against 2% on placebo, including fractures without an obvious fall. The label tells prescribers to consider stopping treatment if a fracture occurs. It is a new risk for a new mechanism, disclosed plainly, and analysts called it unexpected because it had not surfaced clearly in earlier studies.
The Long Road to Approval
The approval took the scenic route. Scholar Rock's first application, filed in September 2025, was rejected before the science was ever reviewed, because of manufacturing compliance problems at the contract facility where the drug was filled, BioPharma Dive reported. The company switched facilities, resubmitted, and won approval roughly two weeks ahead of the FDA's decision deadline. The European application was withdrawn and will be resubmitted with the new facility.
The regulatory designations tell the drug's rarity story: Fast Track, Orphan Drug, and Rare Pediatric Disease, the last of which came with a priority review voucher, a transferable asset companies of Scholar Rock's size sometimes sell for nine figures. That voucher is a second, quieter product of the approval, and it arrives at a company that has spent nine years and most of its capital reaching this moment.
None of that bears on the drug's effect, but it bears on the company. Scholar Rock has never sold a product. It priced Isembyld at roughly $310,000 a year in list terms, disclosed on its investor call, and its stock rose more than 20% on the approval. Analysts project peak sales above $2 billion, a large number for a disease that affects about 10,000 people in the United States, and a sign of how much value the market assigns to the first product in a new layer of treatment.
The commercial machinery is being assembled around the infusion. The company's patient-support program covers coverage questions, financial assistance, and site-of-care navigation, with infusions possible in hospitals, at home, or in infusion centers. The safety database behind the label is broad for a rare disease: more than 500 people treated across studies, some for more than seven years.
Scholar Rock also stands alone in its class. Roche previously discontinued its own muscle-targeting program for SMA, leaving Scholar Rock as the only company to have reached approval with a muscle-directed therapy. The competitive moat, for now, is the whole mechanism.
What This Means for Families
For families living with SMA, the approval adds an option rather than a replacement. The decision is not whether to take the new drug instead of the current one, but whether to add it, with its infusions, its cost, and its fracture risk, to a regimen that is already working in its own way. Some will see a modest average gain and decide the trade is worth it. Others will wait for longer-term data. Both are reasonable readings of the same label.
For payers, the add-on structure raises its own arithmetic. The existing SMN therapies already carry substantial prices, and Isembyld's roughly $310,000 annual list cost stacks on top of them, meaning the combined price of the two-front treatment exceeds what the system has ever paid for SMA care. Whether insurers agree that the added layer earns its cost, and whether the patient-support programs bridge the gaps, is the commercial test the approval just started. The label opens the door. The market decides how wide.
The long-term study is already running, and it will answer the questions the approval did not, including whether gains hold beyond a year and how the fracture risk behaves over time. For a disease where every approved therapy so far has promised preservation, Isembyld's promise is different: building something back. The extension data will show how much, for how long, and at what cost.
There is also a larger question the approval raises for the field: whether the two-front model extends to other neuromuscular diseases. If a muscle-targeting antibody can layer on top of a neuron-targeting therapy in SMA, the same architecture may apply elsewhere, in diseases where existing drugs preserve the nerve and nothing yet helps the muscle. Isembyld's approval is a milestone for one disease and a template for a class. The next drugs built on that template are already the ones to watch.
Primary sources
- FDA, "FDA Approves First Therapy to Target Muscle Loss in Spinal Muscular Atrophy" (Sept. 11, 2026), for the approval, the indication, and the SAPPHIRE results.
- Scholar Rock press release, "Scholar Rock Announces FDA Approval of ISEMBYLD" for the trial data, dosing, safety, and launch details.
- BioPharma Dive, for the manufacturing history, the pricing, and analyst reaction.
- Reuters, "US FDA approves Scholar Rock drug for rare muscle-wasting disease," for the approval and market reaction.